Compare · ENVB vs NVO
ENVB vs NVO
Side-by-side comparison of Enveric Biosciences Inc. (ENVB) and Novo Nordisk A/S (NVO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ENVB and NVO operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $168.79B, about 27526.7x ENVB ($6.1M).
- Over the past year, ENVB is down 87.0% and NVO is down 30.8% - NVO leads by 56.2 points.
- NVO has hit the wire 4 times in the past 4 weeks while ENVB has been quiet.
- NVO has more recent analyst coverage (25 ratings vs 3 for ENVB).
- Company
- Enveric Biosciences Inc.
- Novo Nordisk A/S
- Price
- $1.40-4.76%
- $39.23+2.88%
- Market cap
- $6.1M
- $168.79B
- 1M return
- -7.59%
- -5.98%
- 1Y return
- -87.04%
- -30.85%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- News (4w)
- 0
- 4
- Recent ratings
- 3
- 25
Enveric Biosciences Inc.
Enveric Biosciences, Inc., a pharmaceutical company, engages in developing various cannabinoid medicines for cancer care. It has a pipeline of development programs for radiodermatitis, glioblastoma multiforme, pruritus, rashes, and dry skin and chemotherapy-induced neuropathy. The company is headquartered in Naples, Florida.
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest ENVB
- Enveric Biosciences Secures New U.S. Patent Allowance for Next-Generation, Non-Hallucinogenic Mescaline Derivatives in EVM401 Series
- Enveric Biosciences to Present at H.C. Wainwright 28th Annual Global Investment Conference
- SEC Form 10-Q filed by Enveric Biosciences Inc.
- Enveric Biosciences Reports Financial Results and Provides Corporate Update for Second Quarter 2026
- Enveric Biosciences Reports New Preclinical Data Supporting the Non-Hallucinogenic Profile of Lead Candidate EB-003
- Enveric Biosciences Welcomes Final FDA Guidance for Psychedelic Drug Development
- Enveric Biosciences Announces Participation in B. Riley Securities Mind, Muscle & Vision Summit
- Enveric Biosciences Announces Participation in 2026 BIO International Convention
- Enveric Biosciences Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- SEC Form 424B5 filed by Enveric Biosciences Inc.
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- Novo Nordisk A/S downgraded by Morgan Stanley with a new price target
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- Novo Nordisk A/S downgraded by Deutsche Bank